BioTuesdays

Axsome Therapeutics names David Marek as CCO

Axsome Therapeutics (NASDAQ:AXSM) has appointed David Marek as chief commercial officer, effective Aug. 31.

Mr. Marek joins Axsome from Amgen (NASDAQ:AMGN), where he was most recently VP and general manager of the neuroscience business unit. He was previously VP of marketing of Amgen’s U.S. inflammation and nephrology business. Prior to joining Amgen, Mr. Marek was EVP of consumer services and commercial strategy officer at WebMD; and the managing director of Saatchi & Saatchi Healthcare Advertising.

“Mr. Marek’s expertise in both digital and traditional media, creative commercialization strategies, value and access, and new product launches, is an important addition to Axsome as we create and execute our commercial plans and continue our growth into a leading CNS biopharmaceutical company,” Dr. Herriot Tabuteau, Axsome’s CEO, said in a statement.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.